BACKGROUND: Findings from animal models suggest that selenium supplementation improves glucose metabolism. OBJECTIVE: To examine the effect of long-term selenium supplementation on the incidence of type 2 diabetes. DESIGN: Secondary analysis of a randomized, double-blind, placebo-controlled trial. SETTING: Areas of low selenium consumption of the eastern United States. PATIENTS: 1202 persons seen in dermatology clinics who did not have type 2 diabetes at baseline. INTERVENTION: Oral administration of selenium, 200 microg/d, or placebo. MEASUREMENTS: Incidence of type 2 diabetes. RESULTS: During an average follow-up of 7.7 years (SD, 2.7), type 2 diabetes developed in 58 selenium recipients and 39 placebo recipients (incidence, 12.6 cases per 1000 person-years vs. 8.4 cases per 1000 person-years, respectively; hazard ratio, 1.55 [95% CI, 1.03 to 2.33]). The lack of benefit of selenium supplementation on the incidence of type 2 diabetes persisted in analyses stratified by age, sex, body mass index, and smoking status. An exposure-response gradient was found across tertiles of baseline plasma selenium level, with a statistically significantly increased risk for type 2 diabetes in the highest tertile of baseline plasma selenium level (hazard ratio, 2.70 [CI, 1.30 to 5.61]). LIMITATIONS: Diabetes was a secondary outcome in the parent trial. Diagnoses of diabetes were self-reported but were validated in most participants. The sample was mostly older and white. CONCLUSIONS:Selenium supplementation does not seem to prevent type 2 diabetes, and it may increase risk for the disease. Click here for related information on selenium.
RCT Entities:
BACKGROUND: Findings from animal models suggest that selenium supplementation improves glucose metabolism. OBJECTIVE: To examine the effect of long-term selenium supplementation on the incidence of type 2 diabetes. DESIGN: Secondary analysis of a randomized, double-blind, placebo-controlled trial. SETTING: Areas of low selenium consumption of the eastern United States. PATIENTS: 1202 persons seen in dermatology clinics who did not have type 2 diabetes at baseline. INTERVENTION: Oral administration of selenium, 200 microg/d, or placebo. MEASUREMENTS: Incidence of type 2 diabetes. RESULTS: During an average follow-up of 7.7 years (SD, 2.7), type 2 diabetes developed in 58 selenium recipients and 39 placebo recipients (incidence, 12.6 cases per 1000 person-years vs. 8.4 cases per 1000 person-years, respectively; hazard ratio, 1.55 [95% CI, 1.03 to 2.33]). The lack of benefit of selenium supplementation on the incidence of type 2 diabetes persisted in analyses stratified by age, sex, body mass index, and smoking status. An exposure-response gradient was found across tertiles of baseline plasma selenium level, with a statistically significantly increased risk for type 2 diabetes in the highest tertile of baseline plasma selenium level (hazard ratio, 2.70 [CI, 1.30 to 5.61]). LIMITATIONS: Diabetes was a secondary outcome in the parent trial. Diagnoses of diabetes were self-reported but were validated in most participants. The sample was mostly older and white. CONCLUSIONS:Selenium supplementation does not seem to prevent type 2 diabetes, and it may increase risk for the disease. Click here for related information on selenium.
Authors: Wenfeng Fang; Marci L Goldberg; Nicole M Pohl; Xiuli Bi; Chang Tong; Bin Xiong; Timothy J Koh; Alan M Diamond; Wancai Yang Journal: Carcinogenesis Date: 2010-06-07 Impact factor: 4.944
Authors: María Elena Martínez; Elizabeth T Jacobs; John A Baron; James R Marshall; Tim Byers Journal: J Natl Cancer Inst Date: 2012-04-25 Impact factor: 13.506
Authors: Marco Vinceti; Gabriele Dennert; Catherine M Crespi; Marcel Zwahlen; Maree Brinkman; Maurice P A Zeegers; Markus Horneber; Roberto D'Amico; Cinzia Del Giovane Journal: Cochrane Database Syst Rev Date: 2014-03-30
Authors: Amy J Steuerwald; Patrick J Parsons; John G Arnason; Zhen Chen; C Matthew Peterson; Germaine M Buck Louis Journal: J Anal At Spectrom Date: 2013-06 Impact factor: 4.023
Authors: Abdulaziz M Al-Othman; Zeid A Al-Othman; Gaber E El-Desoky; Mourad A M Aboul-Soud; Mohamed A Habila; John P Giesy Journal: Environ Geochem Health Date: 2012-01-24 Impact factor: 4.609
Authors: Nicole Metes-Kosik; Ivan Luptak; Patricia M Dibello; Diane E Handy; Shiow-Shih Tang; Hui Zhi; Fuzhong Qin; Donald W Jacobsen; Joseph Loscalzo; Jacob Joseph Journal: Mol Nutr Food Res Date: 2012-10-24 Impact factor: 5.914
Authors: Saverio Stranges; Martin Laclaustra; Chen Ji; Francesco P Cappuccio; Ana Navas-Acien; Jose M Ordovas; Margaret Rayman; Eliseo Guallar Journal: J Nutr Date: 2009-11-11 Impact factor: 4.798